Introduction: Anorectal malignant melanoma is an uncommon and highly malignant disease with a greater incidence in females. Many patients were misdiagnosed as hemorrhoids, benign polyps, and rectal cancer. They were often diagnosed in an advanced stage. Wide local excision and abdominoperineal resection are the main treatments of rectal melanoma.
Presentation Of Case: A case report is a 77-year-old man who has blood in the stool for 4 months without clinical examination. He admitted to the emergency room with sudden syndromes that related to bowel perforation. Rectal examination detected a large anorectal polyp. Computer tomography showed free air and fluid in the peritoneal cavity. He was received laparoscopic surgery and found the fishbone penetrated the sigmoid colon without polyp resection. The polyp was treated by local excision a few days later. The histology examination was a primary malignant melanoma. Due to the pigmented lesion that remained from the resected polyp's root, the abdominoperineal resection was performed as a radical treatment.
Discussion: Diagnosis of anorectal malignant melanoma is difficult because of atypical signs, that are confused with bleeding hemorrhoids especially an amelanotic melanoma. Treatment is controversial, including surgery, radiotherapy, chemotherapy, and target therapy. A present case is an option in radical surgery.
Conclusion: Anorectal melanoma is a rare disease with poor results and prognosis. A lack of large-data leads to a missing evidence-based guideline in this disease. Early-staging diagnosis and surgical treatment help patients improve their overall survival.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519280 | PMC |
http://dx.doi.org/10.1016/j.ijscr.2020.09.091 | DOI Listing |
Iran Biomed J
December 2024
Department of medical sciences, Cellular & Molecular Research Center, Qom, Iran.
Sci Rep
December 2024
Interventional Oncology, Johnson & Johnson Enterprise Innovation, Inc, 10th Floor 255 Main St, 02142, Cambridge, Boston, MA, USA.
The introduction of anti-PD-1/PD-L1 therapies revolutionized treatment for advanced non-small cell lung cancer (NSCLC), yet response rates remain modest, underscoring the need for predictive biomarkers. While a T cell inflamed gene expression profile (GEP) has predicted anti-PD-1 response in various cancers, it failed in a large NSCLC cohort from the Stand Up To Cancer-Mark (SU2C-MARK) Foundation. Re-analysis revealed that while the T cell inflamed GEP alone was not predictive, its performance improved significantly when combined with gene signatures of myeloid cell markers.
View Article and Find Full Text PDFCancer Cell Int
December 2024
Department of Plastic and Aesthetic Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China.
Background: Cutaneous melanoma is one of the most invasive and lethal skin malignant tumors. Compared to primary melanoma, metastatic melanoma (MM) presents poorer treatment outcomes and a higher mortality rate. The tumor microenvironment (TME) plays a critical role in MM progression and immunotherapy resistance.
View Article and Find Full Text PDFFitoterapia
December 2024
Department of Chemistry, Universidade Tecnológica Federal do Paraná (UTFPR), Pato Branco, PR 85503-390, Brazil.
This study investigated the antihyperglycemic potential of a hydroalcoholic extract from Syzygium malaccense leaves (E-SM) and isolate phenolic compounds with antioxidant and cytotoxic activities through a bioguided assay. The aim was to explore the therapeutic properties of S. malaccense in managing hyperglycemia and oxidative stress-related conditions.
View Article and Find Full Text PDFEur J Cancer
December 2024
Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, Leiden 2333ZA, the Netherlands; Department of Medical Oncology, Helse Førde, Svanehaugvegen 2, Førde 6812, Norway. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!